论文部分内容阅读
以60名正常人为对照组对比分析58例肺癌患者外周血CD3+细胞、CD4+与CD8+细胞比值（CD4+／CD8+）及血清SIL-2R检测，结果表明：肺癌患者CD3+细胞、CD4+／CD8+均明显低于正常对照，血清SIL-2R水平则明显高于对照组（P＜0．01）。Ⅳ期肺癌血清SIL-2R明显高于Ⅱ、Ⅲ期（P＜0．01），CD3+细胞、CD4+／CD8+明显低于Ⅱ、Ⅲ期肺癌（P＜0．01、P＜0．05）。肺鳞癌组CD4+／CD8+明显低于腺癌组（P＜0．01）。肺鳞癌组与腺癌组CD3+细胞数及血清SIL-2R水平无明显差异。结果认为检测T细胞亚群和血清SIL-2R可作为观察肺癌病情和监测转移情况的指标。
The ratio of CD3+ cells, CD4+ and CD8+ cells (CD4+/CD8+) and serum SIL-2R in peripheral blood of 58 patients with lung cancer were compared and analyzed in 60 normal controls. The results showed that CD3+ cells and CD4+/CD8+ were significantly lower in lung cancer patients. In normal controls, serum SIL-2R levels were significantly higher than those in the control group (P<0.01). The serum levels of SIL-2R in stage IV lung cancer were significantly higher than those in stage II and III (P<0.01). The levels of CD3+ cells and CD4+/CD8+ were significantly lower than those of stage II and III lung cancer (P<0.01, P<0.05). CD4+/CD8+ in the lung squamous cell carcinoma group was significantly lower than that in the adenocarcinoma group (P<0.01). There was no significant difference in the number of CD3+ cells and serum SIL-2R between lung squamous cell carcinoma and adenocarcinoma. The results suggest that the detection of T cell subsets and serum SIL-2R can be used as indicators for the observation of lung cancer conditions and monitoring metastasis.